27.07.2020 • NewsArkemaDede WillamsBostik

Arkema to Acquire Adhesives Producer Fixatti

French chemical producer Arkema is planning to acquire high-performance thermobonding adhesive powders manufacturer Fixatti. The move is aimed at strengthening subsidiary Bostik’s global offering of high value-added technologies in hotmelt adhesive solutions for niche applications in the construction, technical coating, battery, automotive and textile printing industries.

The transaction is foreseen to close in this year’s fourth quarter, subject to approval by antitrust authorities in the relevant countries.

Arkema said the acquisition should complement the organic growth of its Adhesive Solutions segment with high-quality bolt-on acquisitions and also increase this segment’s EBITDA margin to 16% by 2024. The plan also dovetails with its ambition to become a pure specialty materials player by 2024 with the three production segments of Adhesive Solutions, Advanced Materials and Coating Solutions.

With grinding, polymerization and compounding capacities, Fixatti develops and markets a diversified range of high-performance, environmentally friendly thermobonding powders from two sites in Europe and one in China. Arkema said the portfolio addresses many of the bonding issues arising in its customer sectors. The company with 180 employees last reported sales of around €55 million.

Fixatti's copolyester and copolyamide polymerization capabilities are also seen as presenting strong synergies with one of Bostik's historic areas of expertise. Adhesive films manufacturer Prochimir, acquired last year, has a portfolio said to complement the new acquisition from a geographic and technological standpoint.

Arkema said the acquisition plan is in line with its strategy to complement the organic growth of its Adhesive Solutions segment with high-quality bolt-on acquisitions. With a significant potential for synergies, the deal should also contribute to improving the segment’s EBITDA margin to 16% by 2024, it said.

Arkema plans to acquire high-performance thermobonding adhesive powders...
Arkema plans to acquire high-performance thermobonding adhesive powders manufacturer Fixatti, beefing up Bostik’s portfolio of high value-added technologies in hotmelt adhesive solutions for niche applications. The deal is foreseen to close in this year’s fourth quarter. (c) Arkema

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

most read

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.